Influenza antibody and vaccine programs require more than access to an updated viral sequence. Development teams need characterized antigens for screening, reagents for evaluating immune responses, and antibodies that support reliable analytical assays. Connecting these resources is particularly important when comparing candidates across strains or moving from initial binding studies into more detailed characterization.

Sino Biological supports these workflows through its ProVir® viral antigen collection, influenza detection antibodies, and custom protein and antibody development services. Together, these resources give biotechnology and pharmaceutical teams tools for antigen selection, antibody discovery, and preclinical research.

Characterized HA trimers for antibody screening and vaccine research

Hemagglutinin (HA) is a major target in influenza vaccine and antibody development. Its trimeric structure makes protein conformation an important consideration when selecting recombinant reagents for antibody-binding studies.

Sino Biological offers HA trimers with structural characterization by size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS). This analytical approach provides evidence of oligomeric state, complementing purity and binding data when researchers assess a reagent’s suitability for their assay.

One example is the A/Missouri/11/2025 (H1N1) HA Trimer Protein, His Tag (Cat. 41105-V08H). The product is MALS-verified and includes QC-tested binding to the research-grade anti-influenza HA antibody CR9114. In the reported ELISA configuration, immobilized HA binds CR9114 with an EC₅₀ of 0.2–2 ng/mL. These data provide a defined reference for antigen recognition; the reported EC₅₀ is assay-specific and should not be interpreted as an equilibrium affinity or neutralization measurement.

For development teams, this combination of structural and binding characterization supports more informed reagent selection for candidate screening and vaccine-induced antibody-response studies.

Building antigen panels around development objectives

Antibody programs often need to evaluate recognition across multiple influenza strains, while vaccine programs may require reagents representing both the immunizing antigen and comparator strains.

Sino Biological’s influenza vaccine-strain collection includes HA, neuraminidase (NA), and nucleoprotein (NP), with additional formats available for selected strains. Examples include:

These products provide starting points for assembling target-specific panels, with selection guided by each reagent’s construct and validation data.

Historical strain antigens add another dimension to these panels. Comparing candidate binding across selected recent and earlier antigens can help researchers investigate recognition breadth and prioritize follow-up studies. Consistent assay conditions and comparable antigen formats are important when interpreting these results; binding breadth alone does not establish protective activity.

Supporting antigen-specific B-cell discovery

For antibody discovery programs, antigen reagents also play a role in identifying relevant B-cell populations. Sino Biological offers biotinylated HA-specific B-cell probes, including trimeric formats.

The B/Austria/1359417/2021 HA-specific B-cell Probe Trimer (Cat. 40862-V49H1-B), for example, is a biotinylated, MALS-verified construct containing His and AVI tags and a T154G mutation. Its defined construct gives researchers specific features to evaluate when selecting probes for their discovery workflow.

Probe architecture matters because different HA domains and conformations can reveal different antigen-specific B-cell populations. Published research using HA trimer, head, and stem probes illustrates how reagent design influences the populations detected, reinforcing the need to match the probe to the discovery objective.

Detection antibodies for analytical assay development

Alongside antigen reagents, Sino Biological provides influenza antibodies with documented recognition across tested strains and subtypes. These products support teams developing antigen-detection methods and evaluating assay coverage.

Featured reagents include 86001-RM01, a rabbit monoclonal antibody with broad influenza A HA recognition, and 11053-R004, a rabbit monoclonal antibody for influenza B HA. The 11056-MM03 mouse monoclonal antibody targets H3N2 HA. Sino Biological reports Western blot and ELISA validation for these antibodies and provides tested reactivity information to guide selection.

For industry assay teams, these reagents offer starting materials for method development. Performance must then be established in the intended sample matrix, antigen presentation, and assay configuration, including compatibility between capture and detection antibodies where a sandwich format is used.

Extending catalog reagents through custom development

Catalog products address many established targets, but development programs may require proprietary antigen sequences, engineered constructs, or antibodies with specific recognition profiles.

Sino Biological’s custom capabilities include recombinant protein expression and purification, hybridoma development, and single B-cell discovery using FACS and Beacon® platforms. Its influenza research offering also includes custom antibody development and assay kit design, allowing teams to complement available reagents with project-specific development work.

This combination of characterized antigens, detection antibodies, and custom services supports the practical needs of influenza R&D: generating screening materials, comparing candidate recognition, measuring antibody responses, and building analytical methods.

Equip your next influenza development program

Explore Sino Biological’s influenza vaccine-strain antigens and influenza detection antibodies, or discuss a custom protein and antibody project with the team to align reagents and development support with your program’s technical requirements.